Effects of a long-term home-based exercise training programme using minimal equipment vs. usual care in COPD patients: a study protocol for two multicentre randomised controlled trials (HOMEX-1 and HOMEX-2 trials) by Frei, Anja et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Effects of a long-term home-based exercise training programme using
minimal equipment vs. usual care in COPD patients: a study protocol for
two multicentre randomised controlled trials (HOMEX-1 and HOMEX-2
trials)
Frei, Anja ; Radtke, Thomas ; Dalla Lana, Kaba ; Braun, Julia ; Müller, Ramona M ; Puhan, Milo A
Abstract: BACKGROUND Exercise training is an important component of pulmonary rehabilitation
(PR) programmes in chronic obstructive pulmonary disease (COPD), but the great majority of COPD
patients who would benefit from PR never follow such programmes or fail to maintain exercise training
after PR completion. Against this background, we developed an exercise training programme that requires
minimal equipment and can be implemented long-term in the patient’s home-setting. The aims of the
HOMEX-1 and HOMEX-2 trials are to assess the effectiveness of this home-based exercise training
programme in two groups of COPD patients over the course of one year: patients who have completed
PR (HOMEX-1 trial) and patients who did not enrol in existing PR programmes within the last two years
(HOMEX-2 trial). METHODS HOMEX-1 and HOMEX-2 are multicentre, parallel group, randomised
controlled trials. For both trials each, it is planned to include 120 study participants with a diagnosis of
COPD. Participants will be randomised with a 1:1 ratio into the intervention group or the control group
(usual care/no intervention). The intervention consists of minimal-equipment exercise training elements
with progressive level of intensity, conducted by the participant during six days per week and instructed
and coached by a trained health care professional during three home visits and regular telephone calls
during one year. Primary outcome is change in dyspnoea (domain of Chronic Respiratory Questionnaire)
from baseline to 12-months follow-up. Secondary outcomes are change in dyspnoea over the course of the
year (assessed at 3, 6 and 12 month) and change in functional exercise capacity, physical activity, health-
related quality of life, health status, exacerbations and symptoms from baseline to 12 months follow-up. In
addition, explanatory, safety and cost-effectiveness outcomes will be assessed. We will conduct intention-
to-treat analyses separately per trial and per protocol analyses as sensitivity analyses. DISCUSSION The
HOMEX-1 and HOMEX-2 trials assess a novel intervention that provides an innovative way of making
exercise training as accessible as possible for COPD patients. If the intervention proves to be effective
long-term, it will fill the gap of providing an easily accessible and feasible intervention so that more
COPD patients can follow an exercise programme. TRIAL REGISTRATION ClinicalTrials.gov Identifier:
HOMEX-1 NCT03461887 (registration date: March 12, 2018; retrospectively registered); HOMEX-2
NCT03654092 (registration date: August 31, 2018).
DOI: https://doi.org/10.1186/s12890-019-0817-7
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-175257
Journal Article
Published Version
  
The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Frei, Anja; Radtke, Thomas; Dalla Lana, Kaba; Braun, Julia; Müller, Ramona M; Puhan, Milo A (2019).
Effects of a long-term home-based exercise training programme using minimal equipment vs. usual care
in COPD patients: a study protocol for two multicentre randomised controlled trials (HOMEX-1 and
HOMEX-2 trials). BMC Pulmonary Medicine, 19:57.
DOI: https://doi.org/10.1186/s12890-019-0817-7
2
STUDY PROTOCOL Open Access
Effects of a long-term home-based exercise
training programme using minimal
equipment vs. usual care in COPD patients:
a study protocol for two multicentre
randomised controlled trials (HOMEX-1 and
HOMEX-2 trials)
Anja Frei* , Thomas Radtke, Kaba Dalla Lana, Julia Braun, Ramona M. Müller and Milo A. Puhan
Abstract
Background: Exercise training is an important component of pulmonary rehabilitation (PR) programmes in chronic
obstructive pulmonary disease (COPD), but the great majority of COPD patients who would benefit from PR never
follow such programmes or fail to maintain exercise training after PR completion. Against this background, we
developed an exercise training programme that requires minimal equipment and can be implemented long-term
in the patient’s home-setting. The aims of the HOMEX-1 and HOMEX-2 trials are to assess the effectiveness of this
home-based exercise training programme in two groups of COPD patients over the course of one year: patients
who have completed PR (HOMEX-1 trial) and patients who did not enrol in existing PR programmes within the last
two years (HOMEX-2 trial).
Methods: HOMEX-1 and HOMEX-2 are multicentre, parallel group, randomised controlled trials. For both trials
each, it is planned to include 120 study participants with a diagnosis of COPD. Participants will be randomised
with a 1:1 ratio into the intervention group or the control group (usual care/no intervention). The intervention
consists of minimal-equipment exercise training elements with progressive level of intensity, conducted by the
participant during six days per week and instructed and coached by a trained health care professional during
three home visits and regular telephone calls during one year. Primary outcome is change in dyspnoea (domain
of Chronic Respiratory Questionnaire) from baseline to 12-months follow-up. Secondary outcomes are change in
dyspnoea over the course of the year (assessed at 3, 6 and 12 month) and change in functional exercise capacity,
physical activity, health-related quality of life, health status, exacerbations and symptoms from baseline to 12
months follow-up. In addition, explanatory, safety and cost-effectiveness outcomes will be assessed. We will
conduct intention-to-treat analyses separately per trial and per protocol analyses as sensitivity analyses.
Discussion: The HOMEX-1 and HOMEX-2 trials assess a novel intervention that provides an innovative way of
making exercise training as accessible as possible for COPD patients. If the intervention proves to be effective
long-term, it will fill the gap of providing an easily accessible and feasible intervention so that more COPD
patients can follow an exercise programme.
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Background
Exercise training is an important component of pul-
monary rehabilitation (PR) and the management of
COPD [1]. Numerous trials have shown that exercise
training with or without additional PR elements leads
to clinically significant improvements in health-related
quality of life (HRQoL) and exercise capacity in pa-
tients with COPD [2]. However, despite the well-known
benefits, the great majority of patients who would profit
from PR never follow such a programme. On the other
hand, for those patients who undergo a supervised ex-
ercise training programme, it is often challenging to
maintain exercising after PR completion and to imple-
ment the training into the daily life home-setting.
Major barriers for not participating or adhering to pro-
grammes are travel and transport to the centre, disrup-
tion to established routine, lack of perceived benefits,
social isolation, inconvenient timing, comorbidities and
depressive symptoms [3–7].
Traditionally, PR programmes were given under direct
supervision at a rehabilitation centre with participants
attending as inpatients or outpatients. However, both
community-based and home-based programmes are be-
coming increasingly popular [1]. Of the studies included
in the most recent systematic review on the effects of
PR vs. usual care in COPD patients [2], approximately
one third comprised home-based programmes or pro-
grammes that included an element of home-based train-
ing embedded in an inpatient or outpatient setting. Of
the studies that focused on home-based training alone,
the programmes typically lasted eight to twelve weeks,
the follow-up assessments were primarily conducted at
the end of the programme without a more long-term
perspective and their effect on HRQoL and exercise tol-
erance compared to usual care was not consistent across
studies [8–17].
Evidence from two recent trials suggests that the effects
of comprehensive home-based PR programmes were
equivalent or non-inferior to the effects of outpatient PR,
both after completion of the programmes (12 and 8weeks,
respectively) and after one year [18, 19]. These results were
supported by a current systematic review that found similar
beneficial effects of home-based compared to outpatient ex-
ercise training programmes [20]. However, as demonstrated
in other studies [1, 21], in both, the home-based and
outpatient PR groups the strong effects detected immedi-
ately after completion of PR either decreased [18] or van-
ished in the long-term after 12months [19]. Another recent
trial showed beneficial effects of a long-term maintenance
exercise training programme (following PR) after two years;
however, the programme included use of cycle ergometers
which were delivered to the participants’ home, and weight
training. Moreover, patients visited the hospital for super-
vised exercise training sessions on a regular basis [22].
Against this background, we developed a novel exercise
training programme that requires only minimal equip-
ment and that can be easily implemented in the patient’s
home-setting in the long-term (HOMEX intervention).
The overall objectives of the HOMEX-1 and HOMEX-2
trials are to assess the effectiveness of this intervention in
two groups of COPD patients by means of two rando-
mised controlled trials (RCT). The HOMEX-1 trial fo-
cuses on patients who completed PR no longer than one
month ago, aiming at maintaining exercise training effects
elicited during PR for the long-term (post PR maintenance
group). The HOMEX-2 trial focuses on patients who did
not participate in PR within the last two years aiming to
offer a low-threshold complementary option for regular
exercise training in their home setting (no PR group). The
primary objective of the studies is to assess the effect of
the HOMEX intervention on dyspnoea over the course of
one year; secondary objectives are to evaluate the effect of
the intervention on functional exercise capacity, physical
activity, health status, exacerbations and COPD associated
symptoms. Additional objectives are to explore the pa-
tients’ compliance and adherence to the exercise training
programme and to evaluate acceptability, implementation
feasibility and cost-effectiveness of the intervention.
Methods
Study design
HOMEX-1 and HOMEX-2 are multicentre, randomised
(ratio 1:1), parallel group, controlled trials (Clinical
trials.gov Identifier: NCT03461887 and NCT03654092).
Study participants are randomly assigned either to the
home-based exercise group (intervention group) or to
no intervention/usual care (control group). Both trials
were approved by the local ethics committees (Kantonale
Ethikkommission Zürich, Ethikkommission Bern,
Ethikkommission Zentral- und Nordwestschweiz;
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BASEC-Nr. 2017–02092) and are conducted in ac-
cordance with the Declaration of Helsinki and the
EC/ICH-Guidelines on Good Clinical Practice. The
study is restricted to participants who provided writ-
ten informed consent.
Study setting, study population and recruitment
For HOMEX-1, eligible participants are identified from the
Swiss inpatient PR centres Klinik Barmelweid, Berner Reha
Zentrum Heiligenschwendi and Zürcher RehaZentrum
Wald, and the outpatient PR centre Kantonsspital Winter-
thur. All patients admitted to the PR centres will be
screened for study eligibility by the local investigators. Eli-
gible patients will be consecutively informed about the
study and invited to participate. After written informed
consent, baseline assessments will be conducted. Recruit-
ment for HOMEX-1 is planned for 12months; the first par-
ticipant in the first centre was enrolled by the end of
January 2018.
For HOMEX-2, study participants will be primarily re-
cruited in the Canton of Zurich. Potential participants will
be informed about the study by means of information
flyers including a phone number of a contact person of
the Epidemiology, Biostatistics & Prevention Institute
(EBPI), University of Zurich, through direct contact with
LUNGE ZURICH staff (local Lung Association of the
Canton of Zurich), general practitioners and other health
professionals. Additional information on the study is pro-
vided in newsletters of LUNGE ZURICH and/or adver-
tisements and the EBPI homepage. EBPI study staff will
consecutively conduct screening visits at the EBPI in Zur-
ich, where potential participants will be screened for eligi-
bility and receive oral and written information. A
pulmonologist will confirm COPD diagnosis based on a
lung function measurement (portable hand-held spirom-
etry) and assessment of lifetime smoking and occupational
exposure. In case of any uncertainties regarding COPD
diagnosis, the study team will contact the participants’
general practitioner or pulmonologist. After written in-
formed consent, baseline assessments will be conducted.
Recruitment for HOMEX-2 will start by the end of Sep-
tember 2018 and is planned for 12months.
Inclusion criteria
HOMEX-1 and HOMEX-2
– Signed informed consent
– Diagnosis of COPD, defined as forced expiratory
volume in 1 s/forced vital capacity (FEV1/FVC)
ratio < 0.7 and FEV1 < 80% predicted after
bronchodilation, with or without chronic symptoms
(cough, sputum production) corresponding to
GOLD stages II-IV
– Male and female participants ≥40 years of age
– Knowledge of German language to understand study
material and assessments
HOMEX-1 only
– Completion of an inpatient or outpatient PR no
longer than 1 months ago
HOMEX-2 only
– No participation in an inpatient or outpatient PR
within the last two years
Exclusion criteria
HOMEX-1 and HOMEX-2
– Participants not able to conduct the exercise
training programme due to physical, cognitive or
safety reasons, as judged by investigator; e.g., lower
limb joint surgery within preceding three months,
unstable cardiac disease, predominant neurological
limitations
HOMEX-2 only
– Planned participation in a PR programme
Study groups
Participants assigned to the intervention group will re-
ceive the HOMEX intervention (minimal equipment
exercise programme; described below), participants
assigned to the control group will not receive the inter-
vention (usual care). Apart from receiving the HOMEX
intervention or not, the study does not impact any other
planned treatments.
Study intervention
The exercise training programme HOMEX was devel-
oped by health professionals and experts from the EBPI
and thoroughly piloted in several COPD patients by
means of cognitive debriefing techniques (study mater-
ial) and by evaluation of the motivational counselling
strategy, instruction, conduct and feedback of the exer-
cises and optimal scheduling of the home visits and
follow-up calls.
To consider the challenge of conducting regular exercise
training in the long-term, we developed the intervention
under consideration of important determinants of health
behaviour. We therefore aimed to instruct and coach the
minimal equipment exercise training programme to par-
ticipants based on motivational interviewing techniques
and with support of self-management skills like problem
solving, decision making and action planning. The com-
prehensive coaching targets the participant’s behaviour at
various levels; i.e., the individual level (e.g., personal goal
setting), interpersonal level (e.g., social support) and envir-
onmental level (e.g., own flat / house) [23].
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The study intervention consists of three visits at the par-
ticipant’s home by a trained health care professional, the
“personal coach” (mainly physiotherapists, but also other
professions; training and supervision described below), ex-
ercise sessions conducted during six days per week, illus-
trated by cards, an interactive exercise training book and
supporting telephone calls. Additional intervention ele-
ments are that a relative, friend or close person is involved
as a “sparring” partner to support the participant to con-
duct the exercise training programme on a regular basis
and that the general practitioner is informed about the
participation of his/her patient in the intervention.
Initial visit at the participant’s home
At programme onset, the personal coach conducts an ini-
tial visit at the patient’s home (approx. 120min). The aims
of this visit are to establish trust and confidence, to ex-
plore the participant’s ability to perform exercises and to
instruct him/her for the first part of the exercises and the
use of the exercise cards. Besides the cards, the coach in-
troduces the participant also to the daily use of the inter-
active training book in order to report individualised
goals/rewards, record and evaluate daily workouts and de-
fine concrete motivational resources. Furthermore, the
concrete training setting at home, i.e., the precise location
of the chair and the training schedule will be determined.
The communication based on motivational interview
techniques aims to ensure a high level of training adher-
ence throughout the study. The patient is also instructed
to call his coach upon interruptions of training for more
than three consecutive days due to any reason.
Second home visit after three weeks
The aim of the second visit is to further build on trust
and confidence, to instruct the participant in the
remaining exercise cards, to verify exercise performance,
to ensure the regular adaption in training volume and
training intensity, to check the daily entries in the train-
ing book and to discuss and adapt with the participant
short and long term goal attainment.
Third home visit after eight to nine weeks
The aim of the third home visit is to ensure open and
honest communication, the appropriate performance of
all exercises, to check and ensure the regular adaption in
training volume and training intensity, to discuss and
monitor the first short term goal achievement and to
discuss and possibly adapt the long-term goal.
Individualised strength-training programme
The exercise training consists of three trunk, three
upper limb and four lower limb exercises that can be
performed at three different levels. The exercises will be
performed six days per week for about 15–20 min using
a chair and elastic exercise bands on different resistance
levels. The daily strength training is always introduced
by a whole body warm-up and finalised by two or three
appropriate stretching exercises. During the programme,
the intensity of exercises will progressively increase. All
exercises are illustrated on 38 attractive exercise cards
including possible gain, detailed instructions to verify
the correct performance, training volume and intensity.
To document the training progress, the participants will
record their completed training sessions in their training
book which will also be used to monitor training
adherence.
Regular telephone calls
During the 12-month exercise training programme the
personal coaches will regularly call the participants,
directed by a guidance manual to motivate the partici-
pants, to discuss training progress and concrete benefits
and barriers and to adapt goals and the training
programme (exercise intensity, duration) to the individ-
ual needs, if required. During the first ten days, the
coach will call the participant twice, subsequently once
every two weeks for the first 6 months and every five
weeks after, except for situations when training elements
have changed. Participants are instructed to call their
coach if they could not perform the exercises for more
than three consecutive days (i.e., except Sundays), they
will then be followed by additional phone calls. To en-
sure and guide the training restart, additional phone
calls will be conducted, with similar frequency as after
the first home visit. Since motivational components are
a key issue for programme success, the telephone calls
will be based on motivational interview techniques and
target on support in self-management skills to facilitate
a high level of training adherence.
Training and supervision of health care professionals
(“personal coach”)
The health care professionals who will work as personal
coach will be trained by the master coach (KDL, who
was much involved in developing and piloting of the
intervention) during a basis and an update training ses-
sion. For each participant contact (i.e., all 3 home visits
and the telephone contacts), the coach will be provided
with guidance documents with algorithms how to
proceed in specific situations. During the time of the
intervention, the coach will be in regular contact with
the study team as well as part of a virtual chat room
with all other coaches moderated by members of the
study team and supported by the master coach. The
master coach will accompany the coach at least once at
a home visit to ensure the conduct of the intervention
according to protocol (fidelity).
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Study outcomes
Main study outcomes are assessed during study visits be-
fore randomisation at baseline (T0, T1) and at 12-months
follow-up (T4). Further assessments are conducted after 3
months (T2) and after 6 months (T3). Table 1 displays the
study visits and assessment of the outcomes.
Primary outcome
The primary outcome is the change in dyspnoea, measured
by the Chronic Respiratory Questionnaire (CRQ) dyspnoea
domain (standardised version, self-administered) from
baseline until 12-months follow-up [24]. The CRQ dys-
pnoea domain is one of the most commonly used dyspnoea
instrument in trials of PR and contains five questions
responded on a 7-point Likert-type scale ranging from 1
(most severe dyspnoea) to 7 (no dyspnoea).
Secondary outcomes
Secondary outcomes are assessed at baseline and at
12-months follow-up, except for change in CRQ dys-
pnoea subscale, which is additionally assessed at 3 and 6
months follow-up.
Functional exercise capacity
The Six-Minute Walk Test (6MWT) [25, 26] is a vali-
dated and widely used test in COPD patients to assess
functional exercise capacity. The test will be performed
according to European Respiratory Society (ERS)/
American Thoracic Society (ATS) standards [25, 27].
The patients will be instructed to walk as far as possible
during 6 min and they will receive standardized encour-
agements. Two tests will be performed with at least 30
min rest in-between and the test with the higher total
walking distance in meters will be recorded.
The 1-Minute Sit-to-Stand Test (1-min STS test) is a
validated test to assess functional exercise capacity in
individuals with COPD [28]. It counts the number of
repetitions of full sit-to-stand movements from a stand-
ard chair (i.e. standing up and sitting down again) that
a person completes during one minute. The STS move-
ment requires the participant to stand up completely
vertical until in the straight upright position and return
to the sitting position with knees flexed to approxi-
mately 90 degrees. Prior to the STS test participants
will practice the STS movement once or twice in order
to familiarise themselves.
Health-related quality of life (HRQoL)
HRQoL will be assessed by the CRQ domains fatigue,
emotional function and mastery [24]. The whole CRQ (in-
cluding the dyspnoea domain) contains 20 questions
responded to on a 7-point Likert-type scale, ranging from
1 to 7 with lower scores indicating worse HRQoL. HRQoL
will additionally be measured by the EuroQol 5-
Dimension Questionnaire (EQ-5D-5 L) (EuroQoL
Group, www.euroqol.org) including a descriptive sys-
tem for five dimensions (mobility, self-care, usual
activities, pain/ discomfort, anxiety/depression) as well
as a visual analogue scale for overall health state
(feeling thermometer, see below) [29].
Physical activity
Physical activity will be assessed by the clinical visit ver-
sion of PROactive Physical Activity in COPD Instrument
(C-PPAC) in HOMEX-2 participants only. The C-PPAC
is a validated and reliable hybrid tool combining a short
patient-reported outcome questionnaire and two activity
monitor variables (assessed by the ActiGraph® acceler-
ometer, Pensacola, FL, USA) to measure physical activity
in COPD patients in the two domains amount and diffi-
culty (item scores 0–4, scale 0–100) [30, 31]. We will
measure physical activity during one week prior to the
baseline and the 1-years follow-up visit.
Health status and symptoms
Health status and symptoms will be assessed by the
COPD Assessment Test (CAT) which measures the im-
pact of COPD on a person’s health status (8 questions,
6-point Likert-type scale) [32], the feeling thermometer
(FT), a visual analogue scale for overall health state ran-
ging from 0 (worst health you can imagine) to 100 (best
health you can imagine) [33, 34], and of the Hospital
Anxiety and Depression Scale (HADS) which assesses
symptoms of depression and anxiety (14 questions,
4-point Likert-type scale) [35].
Event based exacerbations
Exacerbations are assessed patient-reported at 3-, 6- and
12-months follow-up. Event-based definition requires an
increase in symptoms and an increase in dosage of or
new prescription of systemic corticosteroids and/or
antibiotics.
Explanatory outcomes
Participants’ compliance and adherence to the exercise
training programme (intervention group participants
only) is assessed patient-reported as the percentage of
fulfilled training sessions according to the participants’
handwritten reports in their exercise training books. To
minimise information bias, participants will be informed
by their coaches to fill-in the training books regularly
and truthfully. Furthermore, compliance is assessed from
the health care professionals’ perspective by evaluating
coaches’ reports regarding exercise training interruption
of more than three consecutive days.
Implementation feasibility and acceptability including
satisfaction and experience with the exercise training
programme and health professionals’ feedback on the
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intervention will be assessed by a satisfaction question-
naire and a brief semi-structured interview (participants)
and/or focus groups (with participants and health profes-
sionals separately) at 12-months follow-up. In addition, fi-
delity to programme delivery will be assessed during the
intervention period by the master coach.
Safety outcomes
Serious adverse events (SAEs) that occur after baseline
are sought by non-directive questioning of all partici-
pants at 12-months follow-up. SAEs are also detected
when they are volunteered by the participants during the
course of the study and, for intervention group
Table 1 Schedule of study visits and assessments
1) For T2 and T3 assessments, a questionnaire will be sent by mail to participants. At T3, study staff will also call the participants to verify in detail the questions
regarding cost-effectiveness and other exercise training
2) Randomisation will be conducted at the end of visit T1, after all assessments have been conducted
3) HOMEX-1 participants: measurements are already collected during rehabilitation; HOMEX-2 participants: a lung function measurement will be conducted by a
handheld spirometer
4) HOMEX-2 only
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participants, at every contact. They are documented,
their causal relationship with the intervention is assessed
and they are reported to the responsible ethics commit-
tee according to the legal requirements.
Assessments to adjust per-protocol analysis
The per-protocol analyses will be adjusted based on a new
approach proposed by Miguel Hernán [36] with the fol-
lowing a priori specified factors: 1) Prognostic factors for
the primary outcome dyspnoea, 2) Adherence to conduct
the exercises, and 3) Information whether the participants
conducted other strengthening exercise trainings (for de-
tails see chapter Statistical analyses). Besides the prognos-
tic factors which are already assessed by routinely planned
measurements, we will additionally assess self-efficacy to
conduct the exercise training and information on other
exercise strength trainings by the participants.
Cost-effectiveness outcomes
We will conduct health economic analysis comparing
the relative costs and outcomes (effects) of the inter-
vention and the comparator. Outcomes are assessed
after 3, 6 and 12-months and include 1) Direct health-
care costs (patient-reported: physician visits, specialist
visits, number of hospitalisations, total number of hos-
pitalisation days, number of days in rehabilitation /
study-staff-reported: costs of working hours (adminis-
tration of the intervention, trainings, supervision of the
intervention), costs of intervention material (elastic
bands, training book); 2) Direct non-healthcare costs
(patient-reported: ambulance transportations to hos-
pital (travel costs to usual physician visits are not con-
sidered), nursing home care); and 3) Indirect costs;
mainly productivity loss costs (patient-reported: work-
ing status and disability status due to COPD, workdays
lost due to COPD and related adverse events).
Study visits and procedures
In the course of the study, assessment visits are
planned at baseline (one visit for HOMEX-1 [T1] and
two visits for HOMEX-2 [T0 and T1]) and at
12-months follow-up (T4). The visits are conducted
by trained study nurses at the same location; for
HOMEX-1 at the PR clinics where the study partici-
pants were recruited, for HOMEX-2 at the EBPI in
Zurich. In addition, after 3 (T2) and 6 (T3) months a
questionnaire including the CRQ, cost-effectiveness
outcomes, assessment of other exercise trainings and
prognostic factors for dyspnoea will be sent by mail
to all participants. At 6 months follow-up, study staff
will additionally call the participants to verify in
depth responses regarding cost-effectiveness and other
exercise training. Figure 1 (1a: HOMEX-1, 1b:
HOMEX-2) shows the study flow per participant and
the time schedule of study visits, assessments and
intervention.
Fig. 1 Study flow per participant and overview on time schedule of study visits, assessments and intervention (1a: HOMEX-1, 1b: HOMEX-2)
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Randomisation
Participants will be randomised for each HOMEX-trial
separately, on the level of participants, with a 1:1 ratio,
using block randomisation with varying block sizes, strati-
fied by numbers of repetitions in the 1-min STS test (≤19
vs. > 19 repetitions) and, for HOMEX-1 only, additionally
stratified by study centre. Randomisation is performed by
means of Research Electronic Data Capture (REDCap)
[37], a secure, web-based application specifically designed
to support data capture for research studies which ensures
concealment of random allocation. A biostatistician from
the EBPI who is not involved in the study created for both
HOMEX-trials a separate randomisation list using nQuery
Advisor® + nTerim® 4.0 (Statsols, Cork, Ireland). Another
independent researcher from the EBPI implemented these
lists into the REDCap database. Randomisation will only
take place after all baseline assessments are completed.
Blinding procedures
Due to the kind of intervention, neither participants nor
health care professionals can be blinded after the partici-
pants’ assignment to the intervention or control group.
Data analysts will be blinded to group assignment.
Withdrawal/discontinuation of participants
If a participant withdraws consent, the primary reason
for this decision will be recorded. The exercise training
programme will be discontinued and no further assess-
ments conducted. If a participant is unable to continue
the intervention for an extended period of time (assessed
by the investigators regarding the specific participant
and bearing in mind the participant’s personal situation),
the participant is not considered withdrawn from the
study. If he/she agrees, 12-months follow-up assess-
ments will be conducted; if he/she refuses, follow-up
assessments will be conducted at the time of discontinu-
ation. Compliance/adherence to the study intervention
will be analysed by evaluation the training books, the
conduct of the home visits and regular phone calls and
the records of the coaches’ reports.
Data management
Data will be collected and managed using REDCap data-
base hosted at the Clinical Trials Center (CTC) at the
University Hospital Zurich, Switzerland. Study nurses,
coaches and designated investigator site staff will enter
the data; they will not be given access to the system until
they have been trained. Automatic validation procedures
within the system check for data discrepancies during
and after data entry and, by generating appropriate error
messages, allow the data to be confirmed or corrected
online by the designated investigator site staff.
Monitoring and quality assurance
All study nurses are trained before study onset, a second
training will take place prior to the first 12-months
follow-up visit. EBPI study staff will conduct three moni-
toring visits at each study centre; one 4 to 8 weeks after
the conduction of the first baseline visit, a second after
completion of all baseline assessments and a third
after completion of all 12-months follow-up assessments.
During these visits, the monitor will participate in one
visit and verify whether the participants’ instruction, data
assessment and randomisation are conducted according
to protocol and check whether study procedures, docu-
mentation and REDCap data entry are conducted cor-
rectly. The monitor will check data entries of the
primary and secondary outcomes in the REDCap data-
base. The monitoring records are discussed with the
Principal Investigator and, if necessary, procedures are
derived to improve the quality of data collection, pro-
cesses, documentation and data entry.
All coaches are fully trained before intervention on-
set. During the intervention a regular exchange be-
tween coaches takes place by a protected forum. In
addition, every 3 to 6 months meetings with all coaches
are conducted for exchange purposes. The master
coach accompanies all coaches during one of their first
home visits, checks whether the elements of home
visits have been carried out according to the protocol
and gives feedback to the coaches.
Sample size
For each of the two trials, the sample size calculation is
based on the primary outcome change in the CRQ dys-
pnoea domain from baseline to 12-months follow-up. For
HOMEX-1, the hypothesis is maintenance in intervention
group and decline in control group; for HOMEX-2, the
hypothesis is improvement in the intervention group and
maintenance in control group. The well-established min-
imal important difference of the CRQ dyspnoea scale is
0.5 [38]. Assuming a standard deviation of the outcome
variable of 0.9 [2] (according to the literature we assumed
the same standard deviation of CRQ dyspnoea outcomes
for both patient populations, for those recently completing
PR and for those who did not complete PR within the last
2 years), 80% power and a significance level of 5% (two--
sided), a sample size of 52 patients in each group is re-
quired which results in a total sample size of 120 per trial,
including a drop-out rate of 15% (patients for whom
follow-up assessments are not possible; sample size calcu-
lator: http://hedwig.mgh.harvard.edu/sample_size/js/
js_parallel_quant.html).
Statistical analyses
Analyses are conducted per trial separately. Baseline
characteristics of the study participants are summarised
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according to numbers and percentages for qualitative
variables, mean and standard deviation for quantitative
variables with normal distribution and median and
25th–75th percentiles for quantitative variables with
non-normal distribution. Differences in the change of
the primary outcome CRQ dyspnoea from baseline to
12-months follow-up between the intervention and con-
trol group participants are compared by linear regression
analyses corrected for stratification variables and, if
deemed necessary due to baseline imbalances, potential
confounders. The same analyses are used for continuous
secondary outcomes. Changes in CRQ dyspnoea over
the course of the year (assessed at 3, 6 and 12month)
will be examined using linear mixed models. The ex-
ploratory outcomes compliance to the training, satisfac-
tion and health professionals’ feedback as well as the
implementation process parameters will be analysed
with a mixed-methods approach (using quantitative and
the appropriate qualitative methods). If there is a sub-
stantial amount of missing values, we will compare the
results from the complete case analysis with the results
from a multiple imputation approach.
For the main analyses, we will use an intention-to-treat
approach, i.e., the study participants will be analysed ac-
cording to the group which they were originally rando-
mised to, regardless of whether they adhered to the
intervention according to protocol. Missing follow-up data
of participants who did not conduct 12-months follow-up
assessments will be substituted by the last available meas-
urement (last observation carried forward).
As a sensitivity analysis, we will additionally conduct a
per-protocol analysis, where we will keep only those par-
ticipants in the intervention group who adhered to the
intervention in terms of conducted exercise trainings
[36]. We define adherence to protocol as “conduct of
exercise training sessions at least during 70% of the
weeks within the year of intervention the participants
were able to train at least during 4 times a week”, i.e.,
weeks when participants suffered from pulmonary exac-
erbations or other serious health conditions that pre-
vented them from training are not considered; as
discussed with the coach (definition of a fulfilled indivi-
dualised training session per day [according to protocol:
3 different exercises per day are planned]: conduct of at
least 2 different exercises per day / definition of a ful-
filled week of training [rate of training sessions accord-
ing to protocol: 6 per week]: conduct of at least 3 out of
the planned 6 individualised training sessions per week
on average).
We will adjust the per-protocol analyses with prognos-
tic factors for the primary outcome dyspnoea (dyspnoea,
lung function [FEV1], exercise capacity and events of ex-
acerbations) and for adherence to conduct the exercises
(self-efficacy to conduct the exercises, exercise capacity,
dyspnoea and acute worsening of health state [exacerba-
tions and other]) and with the information whether the
patients conducted other exercise strength trainings.
Concerning the control group, we will collect as much
information as possible, especially with respect to the
type and frequency of self-organised exercise training.
This will also be included in the per-protocol analysis.
The cost-effectiveness of the intervention and com-
parator will be assessed as cost per quality-adjusted life
year (QALY) gained. The analysis will be performed
using a time horizon of one year (i.e., equal to the max-
imal follow-up of the trial) and using a societal perspec-
tive. No interim analyses are planned.
Discussion
The HOMEX-trials addresses two important and long-
existing gaps in the context of PR. First, the study inter-
vention provides an innovative way of making exercise
training as accessible as possible for COPD patients by
introducing a minimal equipment and home-based exer-
cise training programme together with a number of com-
ponents that address important determinants at the
individual level, interpersonal level and environmental
level for performing regular exercise training. Second, in
contrast to many exercise training programmes that have
been tested so far, the study intervention has a long-term
perspective. It is important to highlight that the study
intervention aims to achieve long-term adherence to exer-
cise training by providing a home-based programme that
is supported by health care professionals and others close
to the patients in order to address important determinants
for performing exercise training.
If our home-based minimal equipment exercise train-
ing programme proves to be effective long-term, it will
fill the important gap of providing an easily accessible
and feasible option so that more COPD patients can
follow an exercise programme than it is currently the
case. Furthermore, it will also provide much needed
evidence on how exercise training can be maintained in
the long-term. Thus, the HOMEX trials will address
two key scientific questions in the context of PR for pa-
tients with COPD.
In Switzerland, the Cantonal Lung Associations that
are covering the county already provide services both at
their centres and the patients’ homes. The proposed
intervention has great potential to supplement existing
services with a long-term home-based exercise training
programme option for COPD patients who either are not
willing or not able to participate in existing centre-based
programmes. The Swiss Lung Association could support
the implementation by organizing and providing training
and certification of health care professionals as well by
supporting communication and dissemination in their pa-
tient population. Fortunately, the Swiss Lung Association
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has already expressed interest in taking over our home-
based minimal equipment exercise training programme
and supports its implementation, because it fits well with
their strategic goal of providing important patient-centred
services for individuals with COPD.
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